Vaccinating children in high-endemic rabies regions: what are we waiting for?

Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial

“…However, PrEP is not a routine part of childhood vaccination schedules in most rabiesendemic countries. 5 Under assumptions based on the cost of existing products and comparison, PrEP is only regarded as being a cost-effective option in exceptional circumstances, despite the fact that lifetime risk of death due to rabies exceeds one in 1000 across large areas of Africa and Asia. 1,4,6 Improved access to PEP is typically regarded as a more cost-effective option than PrEP, but the delivery of urgent PEP in remote and unstable settings might prove programm atically challenging.…”

A Cost-Effectiveness Analysis of Pre-Exposure Prophylaxis to Avert Rabies Deaths in School-Aged Children in India

“…The PrEP (I) has been reported to be cost-effective in this study. Moreover, the strategy has been advocated by various researchers in children [ 38 , 39 ]. Therefore, the implementation of the strategy in school-aged children can be an effective strategy in averting rabies deaths in these children.…”

Shaping the future of global access to safe, effective, appropriate and quality health products

“…Rabies vaccination is life-saving, and pre-exposure prophylaxis (PrEP) increases the likelihood of survival in bitten persons. While PrEP is actively promoted in international travellers, it is rarely available or affordable for people at risk in endemic LMICs, even now that simplified schedules and a combined yellow fever/rabies vaccination is available, with lower programmatic costs and improved feasibility 17. When it comes to essential antibiotics, even if access has greatly improved in many countries, their quality assurance remains problematic.…”